[Federal Register Volume 71, Number 174 (Friday, September 8, 2006)]
[Notices]
[Page 53105]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-14872]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Diagnostics of Fungal 
Infections

AGENCY: Technology Transfer Office, Centers for Disease Control and 
Prevention (CDC), Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (DHHS), is contemplating the grant of a worldwide, limited 
field of use, co-exclusive license to practice the inventions embodied 
in the patent and patent applications referred to below to Myconostica, 
Inc. (Myconostica) having a place of business in Manchester, United 
Kingdom. CDC intends to grant no more than three licenses to these 
inventions. The patent rights in these inventions have been assigned to 
the government of the United States of America. The patent and patent 
applications to be licensed are:
    Title: Nucleic Acids for Detecting Aspergillus Species and Other 
Filamentous Fungi.
    U.S. Patent Application Serial No.: 09/423,233.
    Filing Date: 6/27/2000.
    Domestic Status: 6,372,430.
    Issue Date: 4/16/2002.

    Title: Molecular Identification of Aspergillus Species.
    U.S. Patent Application Serial No.: 60/381,463.
    Filing Date: 5/17/2002.
    Domestic Status: Pending.
    Issue Date: N/A.

    Title: Nucleic Acids for the Identification of Fungi and Methods 
for Using the Same.
    U.S. Patent Application Serial No.: 60/325,241.
    Filing Date: 9/26/2001.
    Domestic Status: Pending.
    Issue Date: N/A.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
    Specific DNA (oligonucleotide) probes have been developed for a 
wide variety of systemic disease causing fungi, including Aspergillus 
species and others. A probe has been developed for identification of 
all dimorphic fungi. These probes can be used for the rapid 
identification of fungal pathogens and for the diagnosis of mycotic 
diseases.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Andrew Watkins, Director, Technology Transfer 
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford 
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; 
facsimile: (770) 488-8615. Applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by CDC within sixty days of this notice will 
be considered. Comments and objections submitted in response to this 
notice will not be made available for public inspection, and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552. A signed Confidential Disclosure 
Agreement will be required to receive a copy of any pending patent 
application.

    Dated: August 31, 2006.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
 [FR Doc. E6-14872 Filed 9-7-06; 8:45 am]
BILLING CODE 4163-18-P